As a result, ibrutinib, a BTK inhibitor, suppresses GCN2 activities and synergizes strongly with L-asparaginase in B-ALL, which is currently undergoing clinical trials [60]. This evidence concerns the gene EIF2AK4 and acute lymphoblastic leukemia.